Bristol to produce antibodies using Vical’s platform
Bristol-Myers Squibb Co. has received nonexclusive global rights to DNA drug delivery company Vical Inc.’s DNA immunization technology to produce antibodies for human therapeutic use.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.